Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2013 | short review | Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013

Aggressive lymphoma at ASH 2012: new standards and new perspectives

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2013
Autoren:
Thomas Nösslinger, MD Thomas Nösslinger

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe